Details of the Drug

General Information of Drug (ID: DMZ7XNQ)

Drug Name
Tacrolimus
Synonyms
Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
Indication
Disease Entry ICD 11 Status REF
Organ transplant rejection NE84 Approved [1], [2]
Ocular allergy 4A81 Phase 3 [1], [2]
Therapeutic Class
Immunosuppressive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 804
Topological Polar Surface Area (xlogp) 2.7
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.7 mL/min/kg [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 35 hours (in adult healthy volunteers), 19 hours (in kidney transplant patients), 12 hours (in liver transplants patients), and 24 hours (in heart transplant patients) [4]
Metabolism
The drug is metabolized via the CYP3A4 and secondarily by CYP3A5 [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.24329 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [4]
Vd
The volume of distribution (Vd) of drug is 2.6 +/- 2.1 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.008 mg/mL [3]
Chemical Identifiers
Formula
C44H69NO12
IUPAC Name
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
Canonical SMILES
C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
InChI
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
InChIKey
QJJXYPPXXYFBGM-LFZNUXCKSA-N
Cross-matching ID
PubChem CID
445643
ChEBI ID
CHEBI:61049
CAS Number
104987-11-3
DrugBank ID
DB00864
TTD ID
D06OMK
VARIDT ID
DR00406
INTEDE ID
DR1524
ACDINA ID
D00648

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcineurin (PPP3CA) TTA4LDE PP2BA_HUMAN Inhibitor [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Substrate [12]
Ribosomal 23S RNA methyltransferase Erm (erm) DEW6V07 A0A5N1AHF6_CORAY Substrate [13]
Ribosomal 23S RNA methyltransferase Erm (erm) DEA65D8 A0A381KDL2_CORJE Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Organ transplant rejection
ICD Disease Classification NE84
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calcineurin (PPP3CA) DTT PPP3CA 5.29E-01 1.74E-03 9.99E-03
P-glycoprotein 1 (ABCB1) DTP P-GP 2.00E-01 2.57E-02 6.18E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.05E-02 4.52E-01 5.39E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 8.67E-01 -3.83E-03 -1.24E-02
NADPH-cytochrome P450 reductase (CPR) DME POR 8.69E-02 -1.76E-01 -3.46E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tacrolimus
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Azathioprine. Transplant rejection [NE84] [50]
Coadministration of a Drug Treating the Disease Different from Tacrolimus (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Tacrolimus caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [50]
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Tacrolimus due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [51]
Repaglinide DM5SXUV Moderate Increased plasma concentrations of Tacrolimus and Repaglinide due to competitive inhibition of the same metabolic pathway. Acute diabete complication [5A2Y] [51]
Pioglitazone DMKJ485 Moderate Increased plasma concentrations of Tacrolimus and Pioglitazone due to competitive inhibition of the same metabolic pathway. Acute diabete complication [5A2Y] [51]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Ivosidenib. Acute myeloid leukaemia [2A60] [52]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Midostaurin. Acute myeloid leukaemia [2A60] [53]
Idarubicin DMM0XGL Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [54]
Arn-509 DMT81LZ Major Increased metabolism of Tacrolimus caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [55]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Gilteritinib. Acute myeloid leukaemia [2A60] [56]
Oliceridine DM6MDCF Moderate Increased plasma concentrations of Tacrolimus and Oliceridine due to competitive inhibition of the same metabolic pathway. Acute pain [MG31] [51]
Framycetin DMF8DNE Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Framycetin. Alcoholic liver disease [DB94] [51]
Metronidazole DMTIVEN Moderate Decreased metabolism of Tacrolimus caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [57]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Inotersen. Amyloidosis [5D00] [58]
Siltuximab DMGEATB Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Siltuximab. Anemia [3A00-3A9Z] [58]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Ivabradine. Angina pectoris [BA40] [58]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Bepridil. Angina pectoris [BA40] [53]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Dronedarone. Angina pectoris [BA40] [53]
Nifedipine DMSVOZT Moderate Decreased metabolism of Tacrolimus caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [59]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Tacrolimus and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [60]
Cilostazol DMZMSCT Moderate Increased plasma concentrations of Tacrolimus and Cilostazol due to competitive inhibition of the same metabolic pathway. Arterial occlusive disease [BD40] [51]
Posaconazole DMUL5EW Major Decreased metabolism of Tacrolimus caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [61]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Levalbuterol. Asthma [CA23] [62]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Terbutaline. Asthma [CA23] [63]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Pirbuterol. Asthma [CA23] [63]
Budesonide DMJIBAW Moderate Increased plasma concentrations of Tacrolimus and Budesonide due to competitive inhibition of the same metabolic pathway. Asthma [CA23] [51]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Salbutamol. Asthma [CA23] [62]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Roflumilast. Asthma [CA23] [58]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Formoterol. Asthma [CA23] [63]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [58]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Desipramine. Attention deficit hyperactivity disorder [6A05] [53]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Ofloxacin. Bacterial infection [1A00-1C4Z] [64]
Kanamycin DM2DMPO Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Kanamycin. Bacterial infection [1A00-1C4Z] [51]
Tindamax DM3OWT4 Moderate Decreased metabolism of Tacrolimus caused by Tindamax mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Dalfopristin DM4LTKV Major Decreased metabolism of Tacrolimus caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [65]
Sulfamethoxazole DMB08GE Moderate Increased risk of nephrotoxicity by the combination of Tacrolimus and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [50]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Tacrolimus and Sparfloxacin. Bacterial infection [1A00-1C4Z] [64]
Streptomycin DME1LQN Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Streptomycin. Bacterial infection [1A00-1C4Z] [51]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Gemifloxacin. Bacterial infection [1A00-1C4Z] [64]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Norfloxacin. Bacterial infection [1A00-1C4Z] [64]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Tacrolimus and Rabeprazole. Bacterial infection [1A00-1C4Z] [66]
Netilmicin DMRD1QK Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Netilmicin. Bacterial infection [1A00-1C4Z] [51]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Levofloxacin. Bacterial infection [1A00-1C4Z] [64]
Troleandomycin DMUZNIG Major Increased risk of prolong QT interval by the combination of Tacrolimus and Troleandomycin. Bacterial infection [1A00-1C4Z] [67]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lomefloxacin. Bacterial infection [1A00-1C4Z] [53]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Retigabine. Behcet disease [4A62] [53]
Erdafitinib DMI782S Moderate Increased metabolism of Tacrolimus caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [68]
Etidronic acid DM1XHYJ Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Etidronic acid. Bone paget disease [FB85] [51]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Tacrolimus caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [50]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Eribulin. Breast cancer [2C60-2C6Y] [53]
Talazoparib DM1KS78 Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [69]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lapatinib. Breast cancer [2C60-2C6Y] [53]
Exemestane DM9HPW3 Moderate Increased plasma concentrations of Tacrolimus and Exemestane due to competitive inhibition of the same metabolic pathway. Breast cancer [2C60-2C6Y] [51]
Tucatinib DMBESUA Major Decreased metabolism of Tacrolimus caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Palbociclib DMD7L94 Moderate Decreased metabolism of Tacrolimus caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
Letrozole DMH07Y3 Moderate Increased plasma concentrations of Tacrolimus and Letrozole due to competitive inhibition of the same metabolic pathway. Breast cancer [2C60-2C6Y] [51]
Quinestrol DMJ6H1Z Moderate Increased plasma concentrations of Tacrolimus and Quinestrol due to competitive inhibition of the same metabolic pathway. Breast cancer [2C60-2C6Y] [51]
Cabazitaxel DMPAZHC Moderate Increased plasma concentrations of Tacrolimus and Cabazitaxel due to competitive inhibition of the same metabolic pathway. Breast cancer [2C60-2C6Y] [51]
Bosutinib DMTI8YE Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Bosutinib. Breast cancer [2C60-2C6Y] [58]
Atorvastatin DMF28YC Moderate Increased plasma concentrations of Tacrolimus and Atorvastatin due to competitive inhibition of the same metabolic pathway. Cardiovascular disease [BA00-BE2Z] [70]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Iodipamide. Cholelithiasis [DC11] [71]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [72]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Olodaterol. Chronic obstructive pulmonary disease [CA22] [63]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Vilanterol. Chronic obstructive pulmonary disease [CA22] [62]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Salmeterol. Chronic obstructive pulmonary disease [CA22] [63]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Indacaterol. Chronic obstructive pulmonary disease [CA22] [63]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Arformoterol. Chronic obstructive pulmonary disease [CA22] [63]
Dihydrocodeine DMB0FWL Moderate Increased plasma concentrations of Tacrolimus and Dihydrocodeine due to competitive inhibition of the same metabolic pathway. Chronic pain [MG30] [51]
Ketoprofen DMRKXPT Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Ketoprofen. Chronic pain [MG30] [51]
Fidaxomicin DMFP6MV Minor Decreased clearance of Tacrolimus due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [73]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Isoproterenol. Conduction disorder [BC63] [62]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Drospirenone. Contraceptive management [QA21] [74]
Levonorgestrel DM1DP7T Moderate Increased plasma concentrations of Tacrolimus and Levonorgestrel due to competitive inhibition of the same metabolic pathway. Contraceptive management [QA21] [51]
Levobupivacaine DM783CH Moderate Increased plasma concentrations of Tacrolimus and Levobupivacaine due to competitive inhibition of the same metabolic pathway. Corneal disease [9A76-9A78] [51]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Sevoflurane. Corneal disease [9A76-9A78] [53]
Methoxyflurane DML0RAE Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Methoxyflurane. Corneal disease [9A76-9A78] [51]
Cocaine DMSOX7I Moderate Increased plasma concentrations of Tacrolimus and Cocaine due to competitive inhibition of the same metabolic pathway. Corneal disease [9A76-9A78] [51]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Probucol. Coronary atherosclerosis [BA80] [53]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Tacrolimus and Pasireotide. Cushing syndrome [5A70] [53]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Osilodrostat. Cushing syndrome [5A70] [58]
Lumacaftor DMCLWDJ Major Increased metabolism of Tacrolimus caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [50]
Ivacaftor DMZC1HS Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [75]
MK-8228 DMOB58Q Major Decreased metabolism of Tacrolimus caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [76]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Tacrolimus caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [77]
Sertraline DM0FB1J Moderate Increased plasma concentrations of Tacrolimus and Sertraline due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [51]
Cyclobenzaprine DM1YBRM Moderate Increased plasma concentrations of Tacrolimus and Cyclobenzaprine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [51]
Nefazodone DM4ZS8M Major Decreased metabolism of Tacrolimus caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [61]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Tacrolimus and Escitalopram. Depression [6A70-6A7Z] [53]
OPC-34712 DMHG57U Moderate Increased plasma concentrations of Tacrolimus and OPC-34712 due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [51]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Clomipramine. Depression [6A70-6A7Z] [53]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Doxepin. Depression [6A70-6A7Z] [53]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Maprotiline. Depression [6A70-6A7Z] [53]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [53]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Deutetrabenazine. Dystonic disorder [8A02] [78]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Ingrezza. Dystonic disorder [8A02] [79]
Zonisamide DM0DTF7 Moderate Increased plasma concentrations of Tacrolimus and Zonisamide due to competitive inhibition of the same metabolic pathway. Epilepsy/seizure [8A61-8A6Z] [51]
Felbamate DM1V5ZS Moderate Increased metabolism of Tacrolimus caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [50]
Cenobamate DMGOVHA Moderate Increased metabolism of Tacrolimus caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [50]
Tiagabine DMKSQG0 Moderate Increased plasma concentrations of Tacrolimus and Tiagabine due to competitive inhibition of the same metabolic pathway. Epilepsy/seizure [8A61-8A6Z] [51]
Stiripentol DMMSDOY Moderate Decreased metabolism of Tacrolimus caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Fosphenytoin DMOX3LB Major Accelerated clearance of Tacrolimus due to the transporter induction by Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [55]
Phenobarbital DMXZOCG Major Increased metabolism of Tacrolimus caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Tazemetostat DMWP1BH Moderate Increased metabolism of Tacrolimus caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [50]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Solifenacin. Functional bladder disorder [GC50] [53]
Tolterodine DMSHPW8 Moderate Increased plasma concentrations of Tacrolimus and Tolterodine due to competitive inhibition of the same metabolic pathway. Functional bladder disorder [GC50] [51]
Itraconazole DMCR1MV Major Decreased metabolism of Tacrolimus caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [61]
Miconazole DMPMYE8 Moderate Decreased metabolism of Tacrolimus caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [81]
Ketoconazole DMPZI3Q Major Decreased metabolism of Tacrolimus caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [61]
Ripretinib DM958QB Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [50]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Sunitinib. Gastrointestinal stromal tumour [2B5B] [53]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Tacrolimus caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [50]
Digitoxin DMWVIGP Moderate Increased plasma concentrations of Tacrolimus and Digitoxin due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [51]
Boceprevir DMBSHMF Major Decreased metabolism of Tacrolimus caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [50]
Simeprevir DMLUA9D Moderate Decreased metabolism of Tacrolimus caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [50]
Telaprevir DMMRV29 Major Decreased clearance of Tacrolimus due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [50]
177Lu-DOTATATE DMT8GVU Major Increased risk of nephrotoxicity by the combination of Tacrolimus and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [51]
Rifampin DMA8J1G Major Accelerated clearance of Tacrolimus due to the transporter induction by Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [55]
Rifapentine DMCHV4I Major Increased metabolism of Tacrolimus caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [55]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [82]
MK-1439 DM215WE Minor Increased metabolism of Tacrolimus caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Tacrolimus caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [84]
Cobicistat DM6L4H2 Major Decreased metabolism of Tacrolimus caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Tipranavir DM8HJX6 Moderate Accelerated clearance of Tacrolimus due to the transporter induction by Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [85]
Etravirine DMGV8QU Moderate Increased metabolism of Tacrolimus caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [53]
Darunavir DMN3GCH Major Decreased metabolism of Tacrolimus caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Atazanavir DMSYRBX Major Decreased metabolism of Tacrolimus caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Tacrolimus and Teriflunomide. Hyper-lipoproteinaemia [5C80] [86]
Eprosartan DM07K2I Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Eprosartan. Hypertension [BA00-BA04] [87]
Aliskiren DM1BV7W Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [53]
Captopril DM458UM Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Captopril. Hypertension [BA00-BA04] [87]
TAK-491 DMCF6SX Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and TAK-491. Hypertension [BA00-BA04] [87]
Felodipine DMOSW35 Moderate Increased plasma concentrations of Tacrolimus and Felodipine due to competitive inhibition of the same metabolic pathway. Hypertension [BA00-BA04] [51]
Quinapril DMR8H31 Moderate Decreased absorption of Tacrolimus due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [58]
Telmisartan DMS3GX2 Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Telmisartan. Hypertension [BA00-BA04] [87]
Irbesartan DMTP1DC Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Irbesartan. Hypertension [BA00-BA04] [87]
Conivaptan DM1V329 Major Decreased metabolism of Tacrolimus caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [61]
Givosiran DM5PFIJ Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [51]
Lesinurad DMUR64T Moderate Increased metabolism of Tacrolimus caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [88]
Balsalazide DMO091F Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Balsalazide. Indeterminate colitis [DD72] [51]
Meclofenamic acid DM05FXR Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [51]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Tacrolimus caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [50]
Amobarbital DM0GQ8N Moderate Increased metabolism of Tacrolimus caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [50]
Triazolam DMETYK5 Moderate Increased plasma concentrations of Tacrolimus and Triazolam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [51]
Zaleplon DMGFWSM Moderate Increased plasma concentrations of Tacrolimus and Zaleplon due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [51]
ITI-007 DMUQ1DO Moderate Increased plasma concentrations of Tacrolimus and ITI-007 due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [51]
Quazepam DMY4D87 Moderate Increased plasma concentrations of Tacrolimus and Quazepam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [51]
Estazolam DMZGXUM Moderate Increased plasma concentrations of Tacrolimus and Estazolam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [51]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Polyethylene glycol. Irritable bowel syndrome [DD91] [58]
Naloxegol DML0B41 Minor Decreased clearance of Tacrolimus due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [89]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Tacrolimus caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [58]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Denosumab. Low bone mass disorder [FB83] [90]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Tacrolimus and Crizotinib. Lung cancer [2C25] [91]
Brigatinib DM7W94S Moderate Increased metabolism of Tacrolimus caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [50]
Ceritinib DMB920Z Major Decreased metabolism of Tacrolimus caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [61]
PF-06463922 DMKM7EW Moderate Increased metabolism of Tacrolimus caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [92]
Osimertinib DMRJLAT Moderate Decreased metabolism of Tacrolimus caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [58]
Capmatinib DMYCXKL Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [93]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Tacrolimus and Selpercatinib. Lung cancer [2C25] [58]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Tacrolimus and Lumefantrine. Malaria [1F40-1F45] [50]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Tacrolimus and Halofantrine. Malaria [1F40-1F45] [94]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Primaquine. Malaria [1F40-1F45] [53]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [58]
Idelalisib DM602WT Major Decreased metabolism of Tacrolimus caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [61]
GDC-0199 DMH0QKA Major Decreased clearance of Tacrolimus due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [50]
Moxetumomab pasudotox DMN63DZ Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [51]
IPI-145 DMWA24P Moderate Decreased metabolism of Tacrolimus caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [50]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Arsenic trioxide. Mature B-cell lymphoma [2A85] [95]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Tacrolimus caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [96]
Ibrutinib DMHZCPO Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Ibrutinib. Mature B-cell lymphoma [2A85] [58]
Arry-162 DM1P6FR Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Arry-162. Melanoma [2C30] [50]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Vemurafenib. Melanoma [2C30] [53]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and LGX818. Melanoma [2C30] [97]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Tacrolimus caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [50]
Ethinyl estradiol DMODJ40 Moderate Increased plasma concentrations of Tacrolimus and Ethinyl estradiol due to competitive inhibition of the same metabolic pathway. Menopausal disorder [GA30] [51]
Danazol DML8KTN Moderate Decreased metabolism of Tacrolimus caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [51]
Almogran DM7I64Z Moderate Increased plasma concentrations of Tacrolimus and Almogran due to competitive inhibition of the same metabolic pathway. Migraine [8A80] [51]
Rimegepant DMHOAUG Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Rimegepant. Migraine [8A80] [98]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Exjade. Mineral absorption/transport disorder [5C64] [99]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Tacrolimus due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [53]
Gallium nitrate DMF9O6B Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Gallium nitrate. Mineral excesses [5B91] [51]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Tacrolimus and Panobinostat. Multiple myeloma [2A83] [100]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Thalidomide. Multiple myeloma [2A83] [50]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Tecfidera. Multiple sclerosis [8A40] [101]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Tacrolimus and Siponimod. Multiple sclerosis [8A40] [50]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Tacrolimus and Fingolimod. Multiple sclerosis [8A40] [102]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Ocrelizumab. Multiple sclerosis [8A40] [103]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Tacrolimus and Ozanimod. Multiple sclerosis [8A40] [58]
Deflazacort DMV0RNS Moderate Increased plasma concentrations of Tacrolimus and Deflazacort due to competitive inhibition of the same metabolic pathway. Muscular dystrophy [8C70] [51]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Romidepsin. Mycosis fungoides [2B01] [53]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Tacrolimus caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [50]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Tacrolimus and Nilotinib. Myeloproliferative neoplasm [2A20] [53]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Dasatinib. Myeloproliferative neoplasm [2A20] [104]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [105]
Busulfan DMXYJ9C Moderate Increased plasma concentrations of Tacrolimus and Busulfan due to competitive inhibition of the same metabolic pathway. Myeloproliferative neoplasm [2A20] [51]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Promethazine. Nausea/vomiting [MD90] [53]
Netupitant DMEKAYI Moderate Decreased metabolism of Tacrolimus caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [50]
Metoclopramide DMFA5MY Moderate Altered absorption of Tacrolimus due to GI dynamics variation caused by Metoclopramide. Nausea/vomiting [MD90] [106]
Granisetron DMIUW25 Moderate Increased plasma concentrations of Tacrolimus and Granisetron due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [51]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Ondansetron. Nausea/vomiting [MD90] [53]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Entrectinib. Non-small cell lung cancer [2C25] [50]
Sibutramine DMFJTDI Moderate Increased plasma concentrations of Tacrolimus and Sibutramine due to competitive inhibition of the same metabolic pathway. Obesity [5B80-5B81] [51]
Benzphetamine DMIJATC Moderate Increased plasma concentrations of Tacrolimus and Benzphetamine due to competitive inhibition of the same metabolic pathway. Obesity [5B80-5B81] [51]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Levomethadyl Acetate. Opioid use disorder [6C43] [58]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lofexidine. Opioid use disorder [6C43] [53]
S-297995 DM26IH8 Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [58]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Rucaparib. Ovarian cancer [2C73] [53]
Ibuprofen DM8VCBE Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Ibuprofen. Pain [MG30-MG3Z] [51]
Buprenorphine DMPRI8G Moderate Increased plasma concentrations of Tacrolimus and Buprenorphine due to competitive inhibition of the same metabolic pathway. Pain [MG30-MG3Z] [51]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Triclabendazole. Parasitic worm infestation [1F90] [53]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Pimavanserin. Parkinsonism [8A00] [107]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Tacrolimus caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [50]
Abametapir DM2RX0I Moderate Decreased metabolism of Tacrolimus caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [108]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Famotidine. Peptic ulcer [DA61] [50]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Tacrolimus and Macimorelin. Pituitary gland disorder [5A60-5A61] [109]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Lefamulin. Pneumonia [CA40] [110]
Bromfenac DMKB79O Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Bromfenac. Postoperative inflammation [1A00-CA43] [51]
Ergonovine DM0VEC1 Moderate Increased plasma concentrations of Tacrolimus and Ergonovine due to competitive inhibition of the same metabolic pathway. Postpartum haemorrhage [JA43] [51]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Tacrolimus caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [61]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Ritodrine. Preterm labour/delivery [JB00] [63]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Degarelix. Prostate cancer [2C82] [58]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and ABIRATERONE. Prostate cancer [2C82] [58]
Enzalutamide DMGL19D Major Increased metabolism of Tacrolimus caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [55]
Relugolix DMK7IWL Major Decreased clearance of Tacrolimus due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [111]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Tacrolimus caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [50]
Silodosin DMJSBT6 Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [112]
Dutasteride DMQ4TJK Moderate Increased plasma concentrations of Tacrolimus and Dutasteride due to competitive inhibition of the same metabolic pathway. Prostate hyperplasia [GA90] [51]
Finasteride DMWV3TZ Moderate Increased plasma concentrations of Tacrolimus and Finasteride due to competitive inhibition of the same metabolic pathway. Prostate hyperplasia [GA90] [51]
Ustekinumab DMHTYK3 Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Ustekinumab. Psoriasis [EA90] [58]
Tildrakizumab DMLW9HG Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Tildrakizumab. Psoriasis [EA90] [58]
Risankizumab DMM32GT Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Risankizumab. Psoriasis [EA90] [58]
Ixekizumab DMXW92T Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Ixekizumab. Psoriasis [EA90] [58]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Levomepromazine. Psychotic disorder [6A20-6A25] [53]
Riociguat DMXBLMP Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [50]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Gatifloxacin. Respiratory infection [CA07-CA4Z] [113]
Colistimethate DMZ9BMU Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Colistimethate. Respiratory infection [CA07-CA4Z] [51]
Salsalate DM13P4C Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Salsalate. Rheumatoid arthritis [FA20] [51]
Tocilizumab DM7J6OR Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Tocilizumab. Rheumatoid arthritis [FA20] [58]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Canakinumab. Rheumatoid arthritis [FA20] [58]
Rilonacept DMGLUQS Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Rilonacept. Rheumatoid arthritis [FA20] [58]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Tacrolimus and Golimumab. Rheumatoid arthritis [FA20] [114]
Dexamethasone DMMWZET Moderate Increased metabolism of Tacrolimus caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [50]
Sarilumab DMOGNXY Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Sarilumab. Rheumatoid arthritis [FA20] [58]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Tacrolimus and Leflunomide. Rheumatoid arthritis [FA20] [86]
Quetiapine DM1N62C Moderate Increased plasma concentrations of Tacrolimus and Quetiapine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [51]
Aripiprazole DM3NUMH Moderate Increased plasma concentrations of Tacrolimus and Aripiprazole due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [51]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Tacrolimus and Iloperidone. Schizophrenia [6A20] [53]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Paliperidone. Schizophrenia [6A20] [53]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Tacrolimus and Amisulpride. Schizophrenia [6A20] [115]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Asenapine. Schizophrenia [6A20] [53]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Tacrolimus and Pimozide. Schizophrenia [6A20] [58]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Tacrolimus when combined with Anthrax vaccine. Sepsis [1G40-1G41] [116]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Tacrolimus caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [50]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Tacrolimus caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [58]
Larotrectinib DM26CQR Moderate Decreased metabolism of Tacrolimus caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [50]
Methylprednisolone DM4BDON Moderate Increased plasma concentrations of Tacrolimus and Methylprednisolone due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [51]
Ifosfamide DMCT3I8 Moderate Increased plasma concentrations of Tacrolimus and Ifosfamide due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [51]
Docetaxel DMDI269 Moderate Increased plasma concentrations of Tacrolimus and Docetaxel due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [51]
Armodafinil DMGB035 Moderate Increased metabolism of Tacrolimus caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [50]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Tacrolimus and LEE011. Solid tumour/cancer [2A00-2F9Z] [53]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Tacrolimus and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [53]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [58]
Taxol DMUOT9V Moderate Increased plasma concentrations of Tacrolimus and Taxol due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [51]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [53]
Telavancin DM58VQX Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [51]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Tacrolimus caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [50]
Fostamatinib DM6AUHV Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [117]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [118]
Apixaban DM89JLN Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [58]
Brilinta DMBR01X Moderate Decreased metabolism of Tacrolimus caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [58]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lenvatinib. Thyroid cancer [2D10] [53]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Cabozantinib. Thyroid cancer [2D10] [58]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Tacrolimus and Papaverine. Tonus and reflex abnormality [MB47] [119]
Olsalazine DMZW9HA Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Olsalazine. Ulcerative colitis [DD71] [51]
Plazomicin DMKMBES Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Plazomicin. Urinary tract infection [GC08] [51]
Elagolix DMB2C0E Moderate Increased metabolism of Tacrolimus caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [50]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [120]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Procainamide. Ventricular tachyarrhythmia [BC71] [53]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Propafenone. Ventricular tachyarrhythmia [BC71] [53]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Flecainide. Ventricular tachyarrhythmia [BC71] [53]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Amiodarone. Ventricular tachyarrhythmia [BC71] [53]
Ganciclovir DM1MBYQ Moderate Increased risk of nephrotoxicity by the combination of Tacrolimus and Ganciclovir. Virus infection [1A24-1D9Z] [50]
Valganciclovir DMS2IUH Moderate Increased risk of lowers seizure threshold by the combination of Tacrolimus and Valganciclovir. Virus infection [1A24-1D9Z] [50]
⏷ Show the Full List of 283 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tacrolimus 0.75 mg tablet 0.75 mg 24 HR Extended Release Oral Tablet Oral
Tacrolimus 1 mg tablet 1 mg 24 HR Extended Release Oral Tablet Oral
Tacrolimus 4 mg tablet 4 mg 24 HR Extended Release Oral Tablet Oral
Tacrolimus 1 mg capsule 1 mg Oral Capsule Oral
Tacrolimus 0.5 mg capsule 0.5 mg Oral Capsule Oral
Tacrolimus 5 mg capsule 5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6784).
2 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN: Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. PLoS One. 2018 Apr 11;13(4):e0195764. doi: 10.1371/journal.pone.0195764. eCollection 2018.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
11 Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
12 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
13 High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
24 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
25 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
26 Drug Interactions Flockhart Table
27 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
28 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
29 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
30 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
31 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
32 Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
33 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
34 Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
35 On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
36 Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
37 Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
38 Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
39 Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.
40 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
41 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
42 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
43 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
44 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
45 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
46 Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45.
47 Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8.
48 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
49 Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 2000 Mar;44(3):739-46.
50 Cerner Multum, Inc. "Australian Product Information.".
51 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
52 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
53 Canadian Pharmacists Association.
54 Multum Information Services, Inc. Expert Review Panel.
55 Bhaloo S, Prasad GV "Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report." Transplant Proc 35 (2003): 2449-51. [PMID: 14611983]
56 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
57 Herzig K, Johnson DW "Marked elevation of blood cyclosporine and tacrolimus levels due to concurrent metronidazole therapy." Nephrol Dial Transplant 14 (1999): 521-3. [PMID: 10069238]
58 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
59 Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins R "Nifedipine interaction with tacrolimus in liver transplant recipients." Ann Pharmacother 31 (1997): 571-5. [PMID: 9161650]
60 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
61 Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
62 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
63 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
64 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
65 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
66 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
67 Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
68 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
69 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70 Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]
71 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
72 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
74 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
75 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
76 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
77 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
78 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
79 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
80 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
81 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
82 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
83 Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V "Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient." Fundam Clin Pharmacol 23 (2009): 423-5. [PMID: 19709321]
84 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
85 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
86 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
87 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
88 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
89 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
90 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
91 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
92 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
93 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
94 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
95 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
96 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
97 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
98 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
99 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
100 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
101 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
102 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
103 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
104 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
105 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
106 Prescott WA Jr, Callahan BL, Park JM "Tacrolimus toxicity associated with concomitant metoclopramide therapy." Pharmacotherapy 24 (2004): 532-7. [PMID: 15098810]
107 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
108 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
109 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
110 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
111 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
112 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
113 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
114 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
115 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
116 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
117 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
118 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
119 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
120 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]